Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R
Department of Pharmacology, Merck, Sharp and Dohme Neuroscience Research Laboratories, Harlow, Essex, UK.
Cephalalgia. 1999 Dec;19(10):851-8. doi: 10.1046/j.1468-2982.1999.1910851.x.
This study investigated whether the selective 5HT1F receptor agonist LY334370 has other possible antimigraine mechanisms in addition to the proposed inhibition of dural plasma extravasation. LY334370 (up to 10(-5) M) had no vasoconstrictor effects on human cerebral arteries in vitro. It had no effect (up to 10 mg kg-1, i.v.) on neurogenic vasodilation of dural blood vessels produced by electrical stimulation of the dura mater in anesthetized rats. Nor had it any effect (at 3 mg kg-1, i.v.) on the hyperalgesia produced by injection of carrageenan into the paw of conscious rats or on nociceptive reflex responses in the spinalized, decerebrate rabbit (up to 3 mg kg-1, i.v.), indicating that it has no general analgesic properties. However, it significantly inhibited activation of second-order neurons in the trigeminal nucleus caudalis produced by electrical stimulation of the dura mater in anesthetised rats at 3 mg kg-1, i.v. These results provide evidence to suggest that LY334370 has a central mechanism of action in blocking the transmission of nociceptive impulses within the trigeminal nucleus caudalis and that this may represent a mechanism through which it has its antimigraine effect.
本研究调查了选择性5HT1F受体激动剂LY334370除了所提出的抑制硬脑膜血浆外渗作用外,是否还有其他可能的抗偏头痛机制。LY334370(高达10^(-5) M)在体外对人脑动脉无血管收缩作用。它对麻醉大鼠硬脑膜电刺激所产生的硬脑膜血管神经源性血管舒张无影响(静脉注射高达10 mg kg-1)。它对清醒大鼠爪部注射角叉菜胶所产生的痛觉过敏或对脊髓化、去大脑家兔的伤害性反射反应也无影响(静脉注射3 mg kg-1),这表明它没有一般的镇痛特性。然而,静脉注射3 mg kg-1时,它能显著抑制麻醉大鼠硬脑膜电刺激所引起的三叉神经尾侧核二级神经元的激活。这些结果提供了证据,表明LY334370具有一种中枢作用机制,可阻断三叉神经尾侧核内伤害性冲动的传递,这可能是它产生抗偏头痛作用的一种机制。